Selective D3 Dopamine Receptor Agonists for Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FDA-approved drugs targeting dopamine D2 and D3 receptors lack selectivity, often activating both receptors due to their high homology, leading to unintended side effects and reduced therapeutic efficacy for conditions like Parkinson's disease and neurodegenerative disorders.
Innovation Solution
Development of a compound of Formula I, which selectively activates the D3 dopamine receptor with minimal activation of the D2 receptor, using a specific chemical structure that promotes β-arrestin translocation and exhibits potent agonist activity in D3 G protein-mediated signaling, while avoiding orthosteric binding sites to minimize off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional D3-preferring agonists are used to activate D3 receptor, then neuroprotective effects are achieved, but D2 receptor activation occurs causing impulse control disorders
Solution Approach 1:
The patent applies segmentation by dividing the receptor target into two distinct subtypes (D2 and D3) and designing a compound that selectively targets only the D3 subtype. The indole-piperazine structure with specific substituents creates steric and electronic properties that fit the D3 binding pocket while excluding the D2 receptor, thereby segmenting the pharmacological effect to eliminate off-target D2 activation that causes impulse control disorders.
Solution Approach 2:
The patent employs local quality by modifying specific regions of the molecule (the indole ring and piperazine substituents) to create local chemical properties that interact preferentially with D3 receptor amino acid residues. The R1 and R2 substituents provide local steric bulk and electronic characteristics that match the D3 binding site geometry, creating a localized fit that excludes D2 receptor binding while maintaining D3 agonist activity for neuroprotection.
2Reliability
If orthosteric binding site agonists are used, then D3 receptor activation is achieved, but high homology with D2 receptor causes poor selectivity
Solution Approach 1:
The patent applies dimensionality change by moving from the traditional orthosteric binding site (2D plane) to an allosteric modulator site (3D spatial arrangement). The indole-piperazine structure binds to a distinct allosteric pocket on the D3 receptor that is spatially separated from the orthosteric dopamine binding site. This dimensional shift allows the compound to activate D3 through a different binding geometry that does not cross-react with the highly homologous D2 orthosteric site, achieving precise selectivity.
3Productivity
If D2 and D3 selective modulators are developed, then therapeutic efficacy is improved, but off-target effects on non-target GPCRs occur
Solution Approach 1:
The patent applies parameter changes by systematically varying the chemical parameters of the indole-piperazine core structure (substituent types, positions, and sizes) to optimize binding affinity and selectivity. By adjusting the R1 and R2 substituent parameters, the compound achieves a binding affinity profile that is 100-1000 times higher for D3 compared to D2 and other GPCRs. This parameter optimization ensures high therapeutic efficacy through potent D3 activation while minimizing off-target effects on non-target GPCRs.
Data Source
AI summary
The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereofThe variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula I together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula I is administered to the patient together with one or more additional active agents.